Novartis Reports post-marketing Data for Glofitamab in Parkinson's disease

Novartis today announced post-marketing results for glofitamab in patients with Parkinson's disease. The study demonstrated that glofitamab reduces disease progression risk compared to standard of care or placebo. These results provide important insights into the treatment of Parkinson's disease and support the continued development of glofitamab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.